Androgens and bone: clinical implications for menopausal women

Area of Science:

• Endocrinology
• Gerontology
• Bone Metabolism

Background:

• Osteoporosis is a prevalent skeletal disorder affecting over 28 million Americans, predominantly postmenopausal women.
• Osteoporotic fractures, especially hip fractures, result in significant morbidity and mortality, with an estimated 10-20% mortality rate within a year.
• Despite fracture preventability, many women do not receive adequate medical care for osteoporosis.

Purpose of the Study:

• To review the role of ovarian hormones in the pathophysiology and treatment of postmenopausal osteoporosis.
• To evaluate the efficacy of hormone replacement therapies in preventing osteoporotic bone loss and stimulating bone formation.

Main Methods:

• Review of clinical studies and scientific literature on osteoporosis and hormone replacement therapy.
• Analysis of bone mineral density determinations and bone marker data from relevant studies.

Main Results:

• Estrogen and estrogen-androgen replacement therapies have demonstrated efficacy in preventing osteoporosis development.
• These therapies improve bone mineral density and favorably alter bone marker profiles.
• The addition of androgens to hormone replacement therapy may offer additional benefits in preventing bone loss and promoting bone formation.

Conclusions:

• Hormone replacement therapy, particularly with estrogen and combined estrogen-androgen, is a viable strategy for preventing and treating postmenopausal osteoporosis.
• Androgen supplementation may enhance the bone-protective effects of hormone therapy.
• Further research into optimizing hormone-based treatments is warranted to reduce the burden of osteoporotic fractures.